Extrawell Pharmaceutical Holdings Limited is a company incorporated in Bermuda with limited liability, the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited. It is an investment holding company and the principal activities of its subsidiaries consist of the marketing and distribution of pharmaceutical products to customers in the PRC; the development, manufacture and sales of pharmaceutical products in the PRC; the business of commercial exploitation and development of genome-related technology; and the development and commercialization of oral insulin products (through interest in an associate).
CEPL is located at the Jiutai Economic Development Zone, Changchun, Jilin Province. It is a fully equipped GMP standard factory, built on the land of about 55,000 square meters, with factory area of about 27,000 square meters. CEPL is manufacturing biological products mainly in immunological, cardiovascular, dermatological and antithrombotics categories.
Marketing and distribution of imported pharmaceuticals by SAPL contributed a major part to the revenue of the Group.
Our major products in the market are focusing on central nervous system, antihypertensive and dermatology.
We provide one-stop services from product registration to sales and marketing of pharmaceuticals in China. We are open to collaborate with pharmaceutical manufacturers who are interested in China market.
The Group acquired 100% shares of the company in 2002. This company is engaged in the commercial exploitation and development of genome related technology.
Through acquisition of 51% equity interest of SAL in 2004, the Group is engaged in the development and commercialization of oral insulin products. In July 2013, SAL became a wholly-owned subsidiary of the Group.
As from 28 July 2014, the Group has retained 49% equity interest in SAL as investment in an associate upon completion of the disposal of 51% interest in SAL to United Gene High-Tech Group Limited (now known as Innovative Pharmaceutical Biotech Limited, HKEx 399), a strategic partner in the development of oral insulin products.
We believe the product will significantly enhance the value of the Group's investment in the associate once it is launched to the market.
